Company Profile (AI Text)
Name: KAHF Biotech, Inc.
Canonical URL: https://wefunder.com/kahf.biotech.inc
Updated at: 2026-06-04T23:54:18Z

Tagline: Building a target-centric therapeutic ecosystem for next-generation cancer treatment

Key claims:
- Total raised on Wefunder: 62000 | citation: https://wefunder.com/kahf.biotech.inc#claim-total-raised
- Total investors: 10 | citation: https://wefunder.com/kahf.biotech.inc#claim-total-investors

Verified facts:
- Total raised on Wefunder: 62000 | observed_at: 2026-06-04T23:54:18Z | expires_at: 2026-06-05T23:54:18Z
- Total investors: 10 | observed_at: 2026-06-04T23:54:18Z | expires_at: 2026-06-05T23:54:18Z

Computed metrics:
- total_amount_raised: 62000
- total_investors: 10
- team_size: 1
- featured_investor_count: 1
- faq_count: 0
- recent_post_count: 0

Quick facts:
- A novel target in PDAC with limited prior characterization and promising preclinical validation | citation: https://wefunder.com/kahf.biotech.inc#claim-fact-1
- Dual therapeutic strategy: blocks metastasis early and kills tumors in late-stage disease | citation: https://wefunder.com/kahf.biotech.inc#claim-fact-2
- Capital-efficient plan: lead antibody development achievable at low cost | citation: https://wefunder.com/kahf.biotech.inc#claim-fact-3
- Platform approach expandable to multiple solid tumors expressing the same receptor | citation: https://wefunder.com/kahf.biotech.inc#claim-fact-4
- Lead antibody can be expanded into ADC, CAR-T cells, and Degrader Antibody conjugates (DACs) | citation: https://wefunder.com/kahf.biotech.inc#claim-fact-5
- Founded by PhD cancer scientist with deep expertise in cancer therapeutic development platforms | citation: https://wefunder.com/kahf.biotech.inc#claim-fact-6